Shareprice
20 Sep 2025

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide A/S publishes interim report for the period January – March 2025 – On track – first patients enrolled in CT-005

Regulatory


May 28, 2025

Copenhagen, Denmark, 28 May 2025 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 31 March 2025. The Q1 report is available as an attached document to this press release and on FluoGuide’s website.

FluoGuide had no revenue for the period January 1 to March 31, 2025, and posted a net loss of DKK 8,856 thousand (DKK 7,521 thousand) for the period.

As per March 31, 2025, the cash position was DKK 20,982 thousand (DKK 10,683 thousand). The cash preparedness (cash position + undrawn credit facilities) total approx. DKK 36.5 million. 
The financial result for the period is in line with the Company's expectations.

The total number of shares as of March 31, 2025, amounted to 13,620,149 shares. The total number of shares as of March 31, 2024, amounted to 12,208,384 shares. The average number of shares in Q1 2025 amounted to 13,620,149 shares.

KEY FIGURES Q1 2025 Q1 2024 YTD 2025 YTD 2024 2024
DKK thousand 01-Jan-25 01-Jan-24 01-Jan-25 01-Jan-24 01-Jan-24
  31-Mar-25 31-Mar-24 31-Mar-25 31-Mar-24 31-Dec-24
Net Revenue  0 0 0 0 0
Income before interest and tax (EBIT) -9,621 -8,345 -9,621 -8,345 -33,040
Net result for the period -8,856 -7,521 -8,856 -7,521 -28,959
Cash and bank  20,982 10,683 20,982 10,683 18,608
           
Solvency ratio (%)   45% 29% 45% 29% 81%
Result per share (DKK)  -0.65 -0.62 -0.65 -0.62 -2.23

HIGHLIGHTS DURING Q1:

  • FluoGuide receives approval of CTA for phase II trial in head and neck cancer (CT-005)

HIGHLIGHTS AFTER Q1:

  • FluoGuide enrolls first patient in phase II trial of FG001 for head and neck cancer (CT-005)

“Including the first patient in our phase II trial in head and neck cancer marks an important step forward in our clinical progress and underlines FluoGuide’s ability to execute on its 2025 plan.” says Morten Albrechtsen, CEO at FluoGuide.